European Journal of Cancer
Volume 37, Issue 4 , Pages 447-453 , March 2001

Quality control in the locoregional treatment of breast cancer

  • E.J.Th Rutgers

      Affiliations

    • Corresponding Author InformationTel.: +31-20-512-2551; fax: +31-20-512-2554
    • ,
  • for the EUSOMA Consensus Group

Received 11 August 2000 ,Accepted 24 August 2000.

References 

  1. Blamey RW. The British Association of Surgical Oncology Guidelines for surgeons in the management of symptomatic breast disease in the UK (1998 revision). BASO Breast Specialty Group. Eur J Surg Oncol. 1998;24:464–476
  2. Blichert-Toft M, Smola MG, Cataliotti L, O'Higgins N. Principles and guidelines for surgeons — management of symptomatic breast cancer. European Society of Surgical Oncology. Eur J Surg Oncol. 1997;23:101–109
  3. O'Higgins N, Linos DA, Blichert-Toft M, et al.  European guidelines for quality assurance in the surgical management of mammographically detected lesions. European Breast Cancer Working Group. Eur J Surg Oncol. 1998;24:96–98
  4. Christiaens MR, Cataliotti L, Fentiman I, et al.  Comparison of the surgical procedures for breast conserving treatment of early breast cancer in seven EORTC centres. Eur J Cancer. 1996;32A:1866–1875
  5. EUSOMA . The requirements of a specialist breast unit. Eur J Cancer. 2000;36:2288–2293
  6. Perry NM. on behalf of the EUSOMA Working Party. Quality assurance in the diagnosis of breast disease. Eur J Cancer. 2001;37:159–172
  7. Richards M, Sainsbury R, Kerr D. Inequalities in breast cancer care and outcome. Br J Cancer. 1997;76:634–638
  8. Samant R, Ganguly P. Staging investigations in patients with breast cancer: the role of bone scans and liver imaging. Arch Surg. 1999;134:551–553
  9. Dixon JM, Ravisekar O, Cunningham M, Anderson ED, Anderson TJ, Brown HK. Factors affecting outcome of patients with impalpable breast cancer detected by breast screening. Br J Surg. 1996;83:997–1001
  10. Cady B, Falkenberry SS, Chung MA. The surgeon's role in outcome in contemporary breast cancer. Surg Oncol Clin N Am. 2000;9:119–132viii
  11. Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot J, Jager JJ, et al. The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC ‘boost vs. no boost’ trial. Radiother Oncol. 2000;55:219–232
  12. Vrieling C, Collette L, Fourquet A, et al.  The influence of the boost in breast-conserving therapy on cosmetic outcome in the EORTC “boost versus no boost” trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer. Int J Radiat Oncol Biol Phys. 1999;45:677–685
  13. van Dongen JA, Voogd AC, Fentiman IS, et al.  Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy (European Organization for Research and Treatment of Cancer 10801 trial). J Natl Cancer Inst. 2000;92:1143–1150
  14. Morrow M, Harris JR, Schnitt SJ. Local control following breast-conserving surgery for invasive cancer (results of clinical trials). J Natl Cancer Inst. 1995;87:1669–1673
  15. Morrow M, Harris JR. Local management of invasive breast cancer. 2nd edn. In:  Harris JR,  Lippman ME,  Morrow M,  Osborne CK editor. Diseases of the Breast. Philidelphia: Lippincot Williams Wilkins; 2000;p. 515–560
  16. Overgaard M. Overview of randomized trials in high risk breast cancer patients treated with adjuvant systemic therapy with or without postmastectomy irradiation. Semin Radiat Oncol. 1999;9:292–299
  17. Bijker N, Rutgers EJ, Peterse JL, van Dongen JA, Hart AA, Borger JH, et al. Low risk of locoregional recurrence of primary breast carcinoma after treatment with a modification of the Halsted radical mastectomy and selective use of radiotherapy. Cancer. 1999;85:1773–1781
  18. Sapunar F, Smith IE. Neoadjuvant chemotherapy for breast cancer. Ann Med. 2000;32:43–50
  19. Wolff AC, Davidson NE. Primary systemic therapy in operable breast cancer. J Clin Oncol. 2000;18:1558–1569
  20. Fisher B, Bryant J, Wolmark N, et al.  Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672–2685
  21. Mauriac L, MacGrogan G, Avril A, et al.  Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm (a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS)). Ann Oncol. 1999;10:47–52
  22. Zurrida S, Greco M, Veronesi U. Surgical pitfalls after preoperative chemotherapy in large size breast cancer. Eur J Surg Oncol. 1994;20:641–643
  23. Hortobagyi GN, Singletary SE, Strom EA. Treatment of locally advanced breast cancer. In:  Harris JR,  Lippman ME,  Morrow M,  Osborne CK editor. Diseases of the Breast, 2nd edn. Philidelphia: Lippincot Williams Wilkins; 2000;p. 645–660(Chapter 39)
  24. Esteva FJ, Hortobagyi GN. Locally advanced breast cancer. Hematol Oncol Clin North Am. 1999;13:457–472vii
  25. Schaake-Koning C, van der Linden EH, Hart G, Engelsman E. Adjuvant chemo- and hormonal therapy in locally advanced breast cancer: a randomized clinical study. Int J Radiat Oncol Biol Phys. 1985;11:1759–1763
  26. Bartelink H, Rubens RD, van der Schueren E, Sylvester R. Hormonal therapy prolongs survival in irradiated locally advanced breast cancer (a European Organization for Research and Treatment of Cancer Randomized Phase III Trial). J Clin Oncol. 1997;15:207–215
  27. Fein DA, Fowble BL, Hanlon AL, et al.  Identification of women with T1–T2 breast cancer at low risk of positive axillary nodes. J Surg Oncol. 1997;65:34–39
  28. Maibenco DC, Weiss LK, Pawlish KS, Severson RK. Axillary lymph node metastases associated with small invasive breast carcinomas. Cancer. 1999;85:1530–1536
  29. Silver SA, Tavassoli FA. Mammary ductal carcinoma in situ with microinvasion. Cancer. 1998;82:2382–2390
  30. Wilking N, Rutqvist LE, Carstensen J, Mattsson A, Skoog L. Prognostic significance of axillary nodal status in primary breast cancer in relation to the number of resected nodes. Stockholm Breast Cancer Study Group. Acta Oncol. 1992;31:29–35
  31. Levitt SH. The importance of locoregional control in the treatment of breast cancer and its impact on survival. Cancer. 1994;74:1840–1846
  32. Van de Steene J, Soete G, Storme G. Adjuvant radiotherapy for breast cancer significantly improves overall survival (the missing link). Radiother Oncol. 2000;55:263–272
  33. Cady B. A contemporary view of axillary dissection. Ann Surg. 2000;232:8–9
  34. Recht A. Should irradiation replace dissection for patients with breast cancer with clinically negative axillary lymph nodes?. J Surg Oncol. 1999;72:184–192
  35. Axelsson CK, Mouridsen HT, Zedeler K. Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG). Eur J Cancer. 1992;28A:1415–1418
  36. Chetty U, Jack W, Prescott RJ, Tyler C, Rodger A. Management of the axilla in operable breast cancer treated by breast conservation (a randomized clinical trial. Edinburgh Breast Unit). Br J Surg. 2000;87:163–169
  37. Nieweg OE, Jansen L, Valdes Olmos RA, Rutgers EJ, Peterse JL, Hoefnagel KA, et al. Lymphatic mapping and sentinel lymph node biopsy in breast cancer. Eur J Nucl Med. 1999;26(Suppl. 4):S11–S16
  38. Haigh PI, Giuliano AE. Role of sentinel lymph node dissection in breast cancer. Ann Med. 2000;32:51–56
  39. Giuliano AE. See one, do twenty-five, teach one (the implementation of sentinel node dissection in breast cancer). Ann Surg Oncol. 1999;6:520–521
  40. Hoebers FJ, Borger JH, Hart AA, Peterse JL, Rutgers EJ, Lebesque JV. Primary axillary radiotherapy as axillary treatment in breast-conserving therapy for patients with breast carcinoma and clinically negative axillary lymph nodes. Cancer. 2000;88:1633–1642
  41. Freedman GM, Fowble BL, Nicolaou N, Sigurdson ER, Torosian MH, Boraas MC, et al. Should internal mammary lymph nodes in breast cancer be a target for the radiation oncologist?. Int J Radiat Oncol Biol Phys. 2000;46:805–814
  42. Schwartz GF, Solin LJ, Olivotto IA, Ernster VL, Pressman PI. Consensus Conference on the Treatment of In Situ Ductal Carcinoma of the Breast, April 22–25, 1999. Cancer. 2000;88:946–954
  43. Schnitt SJ, Harris JR, Smith BL. Developing a prognostic index for ductal carcinoma in situ of the breast. Are we there yet?. Cancer. 1996;77:2189–2192
  44. Silverstein MJ, Lagios MD, Groshen S, Waisman JR, Lewinsky BS, Martino S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med. 1999;340:1455–1461
  45. Silverstein MJ. Ductal carcinoma in situ of the breast. BMJ. 1998;317:734–739
  46. Fisher B, Dignam J, Wolmark N, et al.  Lumpectomy and radiation therapy for the treatment of intraductal breast cancer (findings from National Surgical Adjuvant Breast and Bowel Project B-17). J Clin Oncol. 1998;16:441–452
  47. Julien JP, Bijker N, Fentiman IS, et al.  Radiotherapy in breast-conserving treatment for ductal carcinoma in situ (first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group). Lancet. 2000;355:528–533
  48. Hayes DF. Evaluation of patients after primary therapy. In:  Harris JR,  Lippman ME,  Morrow M,  Osborne CK editor. Diseases of the Breast, 2nd edn. Philadelphia: Lippincot Williams Wilkins; 2000;p. 709–730

PII: S0959-8049(00)00386-5

European Journal of Cancer
Volume 37, Issue 4 , Pages 447-453 , March 2001

Article Tools